# DESCRIPTION

## FIELD OF THE INVENTION

- define field of invention

## BACKGROUND

- discuss atherosclerosis and PCSK9

## BRIEF SUMMARY OF THE INVENTION

- introduce PCSK9 inhibitors for atherosclerosis
- describe methods of inhibiting atherosclerotic plaque formation
- outline pharmaceutical compositions and uses

## DETAILED DESCRIPTION

- define scope and terminology

### Methods for Inhibiting Atherosclerosis

- describe methods for inhibiting atherosclerosis
- specify embodiments of selected subjects

### PCSK9 Inhibitors

- define PCSK9 inhibitor
- describe categories of PCSK9 inhibitors
- define proprotein convertase subtilisin/kexin type 9
- describe administration of PCSK9 inhibitor
- define antibody
- describe antigen-binding fragments of antibodies
- describe human antibody
- define recombinant human antibody
- describe isolated antibody
- define specifically binds
- describe exemplary PCSK9 inhibitors

### Preparation of Human Antibodies

- generate human antibodies in transgenic mice
- isolate high affinity chimeric antibodies
- characterize and select antibodies for desirable characteristics
- replace mouse constant regions with human constant regions
- describe specific examples of human antibodies or antigen-binding fragments
- describe properties of antibodies when administered to APOE*3Leiden.CETP mice

### Pharmaceutical Compositions and Methods of Administration

- formulate pharmaceutical compositions with suitable carriers and excipients
- describe various delivery systems and methods of administration
- describe reusable and disposable delivery devices
- describe controlled release systems and unit dosage forms

### Dosage and Administration Regimens

- define therapeutically effective amount
- specify dosage ranges for anti-PCSK9 antibody
- outline sequential administration regimens

### Prior Therapies and Combination Therapies

- describe combination therapies with lipid modifying agents

## EXAMPLES

- provide examples of invention

### Example 1

- generate human antibodies to PCSK9

### Example 2

- study attainment of LDL-C goals in patients at high cardiovascular risk

### Example 3

- study LDL-C goal attainment and lipid-lowering therapy in high cardiovascular risk population

### Example 4

- introduce APOE*3Leiden.CETP mice model
- describe experimental design
- outline methods for plasma lipids and lipoprotein analysis
- detail methods for hepatic LDLR protein levels and lipid analysis
- describe histological assessment of atherosclerosis
- outline methods for flow cytometric analysis and statistical analysis
- present results of MAb316P and atorvastatin treatment on plasma lipids and atherosclerosis
- show effects of MAb316P on liver lipids and fecal bile acid and neutral sterol excretion
- discuss effects of MAb316P on atherosclerosis development and lesion stability

## SUMMARY

- summarize study results

